"Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the disease progression of Parkinson's disease," neuroscientist Xiaobo Mao from ...
15d
Hosted on MSNParkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's ...
Genetic studies have strongly established a prominent role of α-synuclein (α- syn) missense and multiplication mutations in causing Parkinson's disease (PD). In neurons, α-syn is almost ...
He further emphasized that it is more important for them to figure out why injecting alpha-synuclein only gave the mice the initial gut symptoms but not full-blown Parkinson’s disease. Now, he and his ...
Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...
The major mechanism behind Parkinson’s disease is well established – a toxic form of a protein called alpha-synuclein that accumulates inside neurons in clusters, eventually driving cell death ...
Researchers have discovered a new biomarker for Parkinson’s that could ... did not have misfolded alpha-synuclein, suggesting a different biological basis for their disease.
She said: "We're not advocating appendectomy as a form of protecting against Parkinson's disease. "It would be much more wise to control or dampen excessive formation of alpha synuclein to tune ...
Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...
An experimental therapy for Parkinson's disease being developed by ... and also after another alpha-synuclein drug tested in the disease – Biogen's cinpanemab – was abandoned in 2021 after ...
10d
News Medical on MSNAlzheimer’s and Parkinson’s linked to aging brain’s failing waste disposalNew research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results